May 25, 2025 a 12:38 pm
LLY: Analysts Ratings - Eli Lilly and Company
The stock of Eli Lilly and Company, a key player in the pharmaceutical industry, continues to garner robust interest from analysts. With a portfolio addressing critical health issues including diabetes, cancer, and rheumatoid arthritis, the company maintains strong support among analysts, reflected in the steady volume of Buy and Strong Buy ratings. Its strategic collaborations further bolster its position in the healthcare sector.
Historical Stock Grades
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 8 | |
| Buy | 16 | |
| Hold | 5 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
- Over the recent months, the number of Strong Buy and Buy ratings has held steady, indicating consistent confidence among analysts.
- Hold ratings showed slight fluctuations, peaking in February 2025, before a modest decrease.
- Sell and Strong Sell ratings remain minimal, underscoring a predominantly positive outlook.
- The overall count of ratings has largely stabilized, suggesting a clear consensus on the stock's value.
Percentage Trends
- The share of Strong Buy ratings increased from 2024 to 2025, showcasing growing optimism.
- Buy ratings experienced a minor decrement but remained the dominant recommendation over time.
- Hold ratings display a downward trend from late 2024 into 2025.
- The distribution shift towards more definitive Buy recommendations highlights increased analyst confidence.
- Recent months reflect such transitions, with conspicuous reduction in Hold percentages boosting Buy classifications.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-02 | Buy | Buy | UBS |
| 2025-04-28 | Reduce | Buy | HSBC |
| 2025-04-14 | Buy | Buy | Guggenheim |
| 2025-04-09 | Overweight | Overweight | Morgan Stanley |
| 2025-04-08 | Buy | Neutral | Goldman Sachs |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-28 | Reduce | Buy | HSBC |
| 2025-04-08 | Buy | Neutral | Goldman Sachs |
| 2024-08-12 | Buy | Hold | Deutsche Bank |
| 2024-04-03 | Buy | Hold | Erste Group |
| 2024-02-21 | Hold | Buy | DZ Bank |
Interpretation
The consistent trajectory of Buy recommendations reflects strong confidence in Eli Lilly's strategic initiatives, despite occasional downgrades indicating selective concerns. Overall, the analyst sentiment remains positive, with limited skepticism shown through negligible fluctuations in Sell ratings. These patterns reinforce a stable analyst opinion, underpinned by the company’s solid performance metrics and growth potential.
Conclusion
Eli Lilly and Company's enduring appeal to both investors and analysts is evident through the sustained prominence of Buy and Strong Buy ratings. Despite isolated downgrades, the predominant sentiment underlines faith in its long-term growth prospects driven by a diverse product range. As the healthcare sector faces evolving challenges and opportunities, Eli Lilly remains well-positioned, benefiting from strategic collaborations and a robust pipeline. However, industry dynamics warrant continuous monitoring to manage potential risks effectively.